Out of stock
$57.00
Legal Disclaimer
This information has not been reviewed or endorsed by the US FDA. It is provided solely for educational and research purposes. CJC-IPA Blend is not approved for medical use, human consumption, or as a therapeutic treatment.
Product Details
Quantity: 10mg per vial – 5mg CJC-1295 no DAC + 5mg Ipamorelin
Purity: ≥99%, Rigorous third-party testing
Packaging: Secure, sealed, and tamper-proof vials
Source: Synthesized using advanced peptide synthesis techniques. Third-party tested.
Note: This product is sold in lyophilized powder form and must be reconstituted before use.
Overview
CJC-IPA Blend combines two extensively studied peptides—CJC-1295 no DAC and Ipamorelin—for research into growth factor release, recovery mechanisms, and peptide signaling pathways. This synergistic combination is designed to provide both a stimulatory and sustained peptide effect, offering a versatile tool for laboratory studies.
CJC-1295 no DAC is recognized for its ability to stimulate growth-related pathways over a prolonged period, while Ipamorelin is valued for its selective and targeted activity with minimal off-target interaction. Together, they provide a comprehensive platform for advanced peptide research.
Research Specifics
Synergistic Peptide Activity: Studies explore the combined effects of CJC-1295 no DAC and Ipamorelin on growth factor release.
Extended Signaling: CJC-1295 no DAC supports prolonged peptide activity in controlled models.
Selective Action: Ipamorelin provides targeted stimulation with minimal unwanted pathway activation.
Performance & Recovery Models: Blend is used in research examining regeneration and adaptation processes.
Technical Specifications
Molecular Formula: Varies per peptide component
Purity: ≥99%, Rigorous third-party testing
Form: Lyophilized powder
Storage: Store at -20°C for long-term stability
Solubility: Requires reconstitution with sterile bacteriostatic water or a suitable solvent before use
Reviews
There are no reviews yet.